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Finegoldia magna is a member of the normal human bacterial flora on the skin and other non-
sterile body surfaces, but this anaerobic coccus is also an important opportunistic pathogen. SufA
was the first F. magna proteinase to be isolated and characterized. Many bacterial pathogens
interfere with different steps of blood coagulation, and here we describe how purified SufA
efficiently and specifically cleaves fibrinogen in human plasma. SufA is both secreted by F. magna
and associated with the bacterial surface. Successful gene targeting has previously not been
performed in anaerobic cocci, but in order to study the role of the SufA that is present at the
bacterial surface, we constructed an F. magna mutant that expresses a truncated SufA lacking
proteolytic activity. In contrast to wild-type bacteria that delayed the coagulation of human plasma,
mutant bacteria had no such effect. Wild-type and mutant bacteria adhered to keratinocytes
equally well, but in a plasma environment only wild-type bacteria blocked the formation of fibrin
networks surrounding adherent bacteria. The effective cleavage of fibrinogen by SufA suggests
that the interference with fibrin network formation represents an adaptive mechanism of F. magna
with potential implications also for pathogenicity.
INTRODUCTION
The Gram-positive anaerobic coccus Finegoldia magna is
part of the human commensal flora colonizing the human
skin, oropharynx, and gastrointestinal and urogenital tracts
(Murdoch, 1998). It is also an opportunistic pathogen and
the most commonly isolated species among Gram-positive
anaerobic cocci in clinical specimens (Murdoch, 1998).
Typical infections caused by F. magna are soft tissue
infections, wound infections, bone and joint infections and
vaginosis (Bowler & Davies, 1999; Hansson et al., 1995;
Murdoch & Shah, 1999; Stephens et al., 2003). SufA
(Subtilase of Finegoldia magna) is the first described
proteinase of F. magna. This serine proteinase is associated
with the bacterial cell surface, and is also found in
substantial amounts in the bacterial growth medium.
SufA cleaves and inactivates the antibacterial peptide LL-
37 and the chemokine MIG/CXCL9, which also has
antibacterial activity (Egesten et al., 2007; Karlsson et al.,
2007), and homologues of SufA are present in the majority
of F. magna strains (Karlsson et al., 2007), including the
recently published genome of F. magna ATCC 29238 (Goto
et al., 2008).
Many pathogenic bacteria interact with and manipulate the
host coagulation system by activating or repressing homeo-
static factors through proteolytic degradation or protein
binding (for a review see Sun, 2006). Fibrinogen is the major
clotting protein of human plasma, playing key roles in
coagulation and homeostasis. Upon vascular injury, fibrin
polymerization and clotting are initiated by thrombin cleavage
of fibrinogen into fibrin. Fibrinogen consists of three pairs of
non-identical chains, Aa,B b and c, linked together with 29
disulfide bonds in a complex of 340 kDa (Mosesson,
2005). Several bacterial pathogens, Streptococcus pyogenes,
Pseudomonas aeruginosa, Porphyromonas gingivalis and
Treponema denticola, produce fibrinogen-degrading protein-
ases (for references see Travis & Potempa, 2000). In addition, a
cysteine proteinase of Staphylococcus epidermidis (Oleksy et al.,
2004) and subtilases of group B streptococci (Harris et al.,
2003) and the fungus Acremonium (Liu et al., 2007) have been
reported to cleave fibrinogen, suggesting that this mechanism
plays an important role in many host–microbe relationships.
In the present study we demonstrate that purified and
soluble SufA efficiently cleaves fibrinogen in plasma, and
Abbreviations: aC, C-terminal domain of fibrinogen Aa chain; CDS,
coding sequence; FPA, fibrinopeptide A; FPB, fibrinopeptide B; SufA,
subtilase of Finegoldia magna; TCT, thrombin-induced coagulation time.
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the formation of fibrin networks. We also describe the first
example of gene targeting in a Gram-positive anaerobic
coccus.
METHODS
Proteins, bacterial strains and growth conditions. Human serum
albumin and fibrinogen were purchased from Sigma. Finegoldia
magna strain ALB8 isolate was from Lund University Hospital, Lund,
Sweden and has been described earlier (de Cha ˆteau & Bjo ¨rck, 1994).
Bacteria were grown under strict anaerobic conditions (Anaerobic
Workstation, Elektrotek) in Todd–Hewitt broth (TH, Difco)
supplemented with 0.5% (v/v) Tween-80. For cultivation of F.
magna mutant CK05, 200 mg kanamycin ml
21 was added. Escherichia
coli TOP10 was purchased from Invitrogen and cultured in Luria
broth (LB, Difco). Recombinantly expressed SufA is described
elsewhere (Karlsson et al., 2007). For native SufA purification, F.
magna bacteria were treated with papain, and SufA was purified as
described earlier (Karlsson et al., 2007). Briefly, following the
digestion, papain was inactivated by adding E64, the supernatant
was collected by centrifugation and papain was removed by dialysis.
The proteins were then separated by ion-exchange chromatography
and fractions containing SufA were further purified by gel filtration.
Fractions were analysed by SDS-PAGE, Western blotting using
antibodies against recombinant SufA as probe, and gelatin zymo-
graphy. Also, crude papain digests and concentrated growth medium
from ALB8 and the mutant CK05 were analysed by Western blotting
and gelatin zymography.
SDS-PAGE, mass spectrometry, immunoblotting and zymogra-
phy. SDS-PAGE was performed as described by Laemmli (1970) using
a total polyacrylamide concentration of 8% or 10%, and 3.3% cross-
linking. Gels were stained with Coomassie R-250 or separated
proteins were transferred onto an Immobilon-P membrane
(Millipore) by using the Mini Trans-Blot system (Bio-Rad). SufA
was detected with antibodies raised against recombinant SufA
(1:1000) (Karlsson et al., 2007). Human tissue factor monoclonal
antibodies were purchased from American Diagnostica. The mono-
clonal antibody against bovine osteonectin/BM-40, developed by Dr
John D. Termine, was obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD and
maintained by The University of Iowa, Department of Biological
Sciences, Iowa City, IA 52242, USA. Bound antibodies were detected
by using horseradish peroxidase-conjugated goat anti-rabbit IgG or
goat anti-mouse IgG (Bio-Rad) and Supersignal West Pico chemi-
luminescent substrate (Pierce).
Coomassie R-250-stained bands of interest were excised from SDS-
PAGE gels and analysed by matrix-assisted laser desorption/
ionization-time of flight mass spectrometry (MALDI-TOF MS).
Briefly, the excised protein bands were destained and enzymically
digested with trypsin (Promega). The tryptic peptides were then
spotted onto a MALDI target plate. MALDI-MS mass spectra were
acquired on a MALDI micro MX mass spectrometer (Waters)
followed by automated protein identification by protein mass
fingerprinting searching the Swiss-Prot database, limited to Homo
sapiens, with the search engine MASCOT (http://www.matrixscien-
ce.com). The following matcher parameters were used: constant
modification of cysteine by carbamidomethylation, variable modi-
fication of methionine by oxidation. MALDI-TOF was carried out at
the SCIBLU proteomics resource centre at Lund University (http://
www.lth.se/sciblu/).
For zymography, protein samples were dissolved in non-reducing
sample buffer and incubated for 5 min at room temperature. Proteins
were separated by SDS-PAGE using 8% polyacrylamide gels
containing 0.1% porcine gelatin (Bio-Rad). After electrophoresis,
gels were incubated in 2.5% Triton X-100 for 30 min at 37 uC,
washed in 50 mM Tris/HCl pH 7.5, 0.2 M NaCl and 5 mM CaCl2
and then incubated for 18 h in the same buffer. Areas of proteolytic
activity were detected by Coomassie R-250 staining of the gel (Liotta
& Stetler-Stevenson, 1990).
F. magna transformation. The transformation protocol used for
Streptococcus pyogenes (Simon & Ferretti, 1991) was modified for F.
magna. A 10 ml solution of stationary-phase bacteria was centrifuged
and washed with water, followed by 0.5 M sucrose, and then
resuspended in 0.1 ml 0.5 M sucrose. To 100 ml of the bacterial cell
solution 5 mg DNA was added and the bacteria were electroporated
using the Gene Pulser II system (Bio-Rad) with settings 2.3 kV, 3 mF,
800 V in 2 mm cuvettes. Electroporated bacteria were incubated in
10 ml TH medium, supplemented with 0.5% Tween-80 and 10%
fetal calf serum, for 18 h in an anaerobic environment for phenotypic
expression. Appropriate antibiotics were added to the bacterial
culture for selection (100 mg kanamycin ml
21) and incubation was
continued for 3 days. The culture was then plated on TH-agar plates
containing the same antibiotic as above.
Mutagenesis of sufA in F. magna ALB8. For insertional gene
disruption of sufA, plasmid pFW13 (GenBank accession number
U50978) was used for genomic integration of a truncated sufA gene. A
PCR product covering bp 90–1100 of the sufA coding sequence (CDS)
(GenBank accession number DQ679960) was amplified from F.
magna ALB8 genomic DNA using primers forward 59-CTCGAG-
GATAGCACTACATATGCCAAACTTCA-39 and reverse 59-AAGC-
TTGTCAGGGTTGATAGCTAAGTTAGTCTT-39. The forward pri-
mer incorporated a XhoI restriction site and the reverse included a
HindIII site (underlined). The product was cloned into pCR4-Topo
vector (Invitrogen) according to the manufacturer’s protocol. The
pCR4-Topo:sufA vector was digested with XhoI and HindIII. The
1010 bp sufA fragment was ligated into XhoI- and HindIII-digested
pFW13. The ligation was transformed into E. coli TOP10 cells
(Invitrogen) and transformants were selected for kanamycin resist-
ance. Purified pFW13-sufA plasmid was then used for electroporation
of F. magna ALB8 bacteria (see above). Mutants were analysed using
PCR with the following primer combinations: PCR1 forward 59-
CAAGGCGTAAAGGCAGACCAAC-39 and reverse 59-CCTCCTTTT-
GGTTACCTCAC-39; PCR2 forward 59-TCTTTTCTACGGGGTC-
TGAC-3 and reverse 59-CAGTAGCATCAATGGAAAATACAA-39;
PCR3 forward 59-CAAGGCGTAAAGGCAGACCAAC-39 and reverse
59-TCTACTGTAACCTGAACCCATTCCC-39. Crude protein extracts
and concentrated growth media of the mutants were analysed using
antibodies against recombinant SufA and with gelatin zymography.
One clone, designated CK05, was chosen for further analysis with
DNA sequencing and Southern blotting.
Southern blots. F. magna chromosomal DNA was isolated by using
the Gentra Puregene kit with the following modification: the bacteria
were incubated with 1 U mutanolysin (Sigma) per mg cells in TE-
buffer (10 mM Tris/HCl pH 7.5 and 1 mM EDTA) at 37 uC for 18 h
before cell lysis.
Internal fragments of the sufA (bps 39–495 of the CDS) gene and the
pFW13 kanamycin-resistance gene aacA/aphD (bps 346–822 of the
CDS) to be used as Southern blot probes were cloned as follows:
ALB8 chromosomal DNA was amplified with primers forward 59-
TTGTTTTCATTGGCATTACC-39 and reverse 59-CAAGGCTGATA-
CTTTGTGGG-39, and plasmid pFW13 was amplified with primers
forward 59-ATACAGAGCCTTGGGAAGAT-39 and reverse 59-GGTA-
GTGGTTATGATAGTGTGGCA-39. The generated PCR products
were purified and biotin-labelled using the Biotin DecaLabel kit
(Fermentas). Three micrograms of chromosomal DNA from ALB8
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hybridization signals were detected with the Biotin Chromogenic
Detection kit (Fermentas) according to the standard protocol
recommended by the manufacturer.
Clotting assays. Fibrinogen polymerization was measured in a
coagulometer (Amelung). SufA purified from the cell surface of the
ALB8 strain (Karlsson et al., 2007) or bacterial suspensions (30 mlo f
10
8,5 610
8 or 10
9 c.f.u. in 13 mM sodium citrate buffer) was
incubated with 100 ml citrate-treated plasma (Lund University
Hospital) or fibrinogen (Sigma) solution (3 mg ml
21 in 13 mM
sodium citrate buffer) for 30 min at 37 uC. Samples incubated with
bacteria were pelleted and 100 ml of the resulting supernatants was
clotted by the addition of 100 ml thrombin clotting time (TCT)
reagent (Haemoclot Thrombin Time, Hyphen Biomed). Clotting of
supernatants from SufA-treated plasma was also initiated by the
addition of 100 ml DAPTTIN (Technoclone) for 200 s at 37 uC
followed by addition of 100 ml 25 mM CaCl2 (for activated partial
thromboplastin time, aPTT) or 200 ml ThromboMAX with calcium
(for prothrombin time, PT; Trinity Biotech). The concentration of
fibrinopeptide A (FPA) following SufA cleavage of fibrinogen was
measured by using a FPA ELISA kit from Haemochrom Diagnostica.
Cell culture and adherence assay. A human keratinocyte cell line
(HaCaT) was used to test adherence of F. magna. Cells were cultured
in serum-free medium (K-SFM) supplemented with 5 ng recombin-
ant human epidermal growth factor (EGF) ml
21,5 0 mg bovine
pituitary extract ml
21 and 650 ng gentamicin ml
21 (all from Gibco-
BRL, Invitrogen), at 37 uC in an atmosphere containing 5% CO2 with
100% relative humidity. Cells were grown to monolayer and
confluence on Thermanox coverslips (Nunc) placed in a 24-well
culture plate or directly in 24-well culture plates. Monolayers were
washed three times with PBS and infected with 10
8 c.f.u. bacteria for
2 h at 37 uC. Infected monolayers were washed three times with PBS
to remove non-adherent bacteria and then incubated with citrate-
treated plasma or PBS for 15 min at 37 uC. After washing as above,
the cells were prepared for analysis by electron microscopy.
Keratinocyte proteins for immunoblotting were extracted from
confluent monolayers with 20% SDS buffer and boiling. Proteins in
keratinocyte conditioned media were precipitated with acetone.
Electron microscopy. For scanning electron microscopy, cells and
bacteria on coverslips were fixed in 2% (v/v) glutaraldehyde, 0.1 M
sodium cacodylate, 0.1 M sucrose, pH 7.2, for 1 h at 4 uC, and
washed with 0.15 M cacodylate, pH 7.2. The samples were post-fixed
with 1% (w/v) osmium tetroxide, 0.15 M sodium cacodylate, pH 7.2,
for 1 h at 4 uC, washed, and stored in cacodylate buffer. The samples
were dehydrated with an ascending ethanol series (10 min per step),
dried, mounted on aluminium holders, sputtered with palladium/
gold, and examined in a JEOL JSM-350 scanning electron
microscope.
For transmission electron microscopy, cells and bacteria in 24-well
culture plates were harvested with a scraper and fixed for 1 h at room
temperature and then overnight at 4 uC in 2.5% glutaraldehyde in
0.15 M sodium cacodylate, pH 7.4 (cacodylate buffer). Samples were
washed with cacodylate buffer and post-fixed for 1 h at room
temperature in 1% osmium tetroxide in cacodylate buffer, dehy-
drated in a graded series of ethanol, and then embedded in Epon 812
(SPI Supplies) using acetone as an intermediate solvent. Specimens
were sectioned with a diamond knife into 50–70 nm thick ultrathin
sections on an LKB ultramicrotome. The ultrathin sections were
stained with uranyl acetate and lead citrate. Specimens were observed
in a JEOL JEM 1230 electron microscope operated at 80 kV
accelerating voltage. Images were recorded with a Gatan Multiscan
791 CCD camera.
For negative staining, 3 mg fibrinogen ml
21 was incubated with
30 nM SufA or PBS at 37 uC for 1 h. Samples were adsorbed onto a
400-mesh carbon-coated copper grid, which was rendered hydro-
phobic by glow discharge at low pressure in air. The grid was
immediately blotted, briefly washed with two drops of water, and
stained with 0.75% uranyl formate for 15 s. Specimens were studied
in a JEOL 1200 Ex transmission electron microscope operated at
60 kV accelerating voltage and 675000 magnification.
RESULTS
SufA cleaves fibrinogen in human plasma
In order to investigate whether SufA is proteolytically active
on plasma proteins, the enzyme was purified from the cell
surfaceofF.magnaALB8aspreviouslydescribed(Karlssonet
al., 2007). SufA, at concentrations of 3 nM or 30 nM, was
incubated for 1 h with human plasma, and two prominent
degradation products with apparent molecular masses of 32
and 35 kDa were detected by SDS-PAGE (Fig. 1a, lanes 2 and
3). MS analysis of these protein bands identified both
cleavage products as fibrinogen Aa-chain fragments. All
matched peptides were identified in the NH2-terminal
region, suggesting that SufA may release a C-terminal
fragment of the Aa chain from the fibrinogen molecule
(Table 1,samples1and 2).Thecleavageoffibrinogenisrapid
as judged from incubations of plasma and SufA for various
time points, and after 5 min of incubation, degradation
products could already be seen (data not shown). No other
proteins could be identified in the protein bands using the
MASCOT search engine and based on the probability-based
Mowse scoring. The C-terminal Aa chain is known to be
particularly susceptible to proteolysis and lower forms are
generally present in plasma fibrinogen, explaining the weak
band of 35 kDa present in the PBS control (Fig. 1a, lane 1)
(Weisel, 2005). To further confirm the fibrinogen-cleaving
activity, purified fibrinogen was incubated with SufA and
again the 32 and 35 kDa degradation products were
generated (Fig. 1b). In addition, a fragment of approximately
58 kDa appeared. Mass spectrometry identified the 58 kDa
fragment as the Bb chain of fibrinogen, with peptide masses
matching sequences between residues 164 and 491 (including
theabsoluteCterminus)(Table1,sample5).Thetwosmaller
fragments were identified as the Aa chains, with matching
peptides between residues 49 and 287 (Fig. 1b, Table 1,
samples 3 and 4). Electron microscopy analysis following
negative staining of fibrinogen cleaved by SufA revealed no
visible differences as compared to untreated fibrinogen (data
not shown), indicating that the overall structure of the
molecule remains intact although portions of extending
polypeptidechainsareremoved.Aschematicdepictionofthe
fibrinogen molecule with the predicted SufA cleavage sites is
shown in Fig. 1(c). Other major human plasma proteins
(albumin and IgG) were not degraded by SufA (data not
shown). However, it cannot be excluded that less abundant
plasma proteins are cleaved by the enzyme.
To investigate the interactions between fibrinogen and
SufA, fibrinogen was directly applied to a PVDF membrane.
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240 Microbiology 155Fig. 1. SufA degrades and binds fibrinogen. Human citrate-treated plasma or fibrinogen solution (3 mg ml
”1) was incubated
with SufA purified from the cell surface of F. magna and analysed by SDS-PAGE. Degradation products were identified by mass
spectrometry. (a) A 10 ml aliquot of 5% human plasma was incubated for 60 min at 37 6C with: lane 1, PBS; lane 2, 3 nM
SufA; lane 3, 30 nM SufA. Degradation products in lanes 2 and 3, marked with an arrowhead, were identified by MALDI-TOF.
(b) A 10 mg aliquot of human fibrinogen was incubated for 60 min at 37 6C with: lane 1, PBS; lane 2, 30 nM SufA. The
positions of fibrinogen Aa,B b and c chains are shown in lane 1. Degradation products in lane 2 were identified by MALDI-TOF
as indicated (D). (c) Schematic representation of fibrinogen with predicted SufA cleavage sites. The Aa,B b and c chains of
fibrinogen are represented by bars proportional to the numbers of amino acid residues in each chain without the signal peptide.
The NH2 and C termini are labelled N and C. Intrachain disulfide bonds are indicated with solid lines. Interchain disulfide bonds
are not shown. Thrombin cleavage sites are indicated with small arrows and SufA cleavage sites are indicated with large arrows.
(Adapted from Weisel, 2005.) (d) Various amounts of fibrinogen (lane 1) and 5 mg recombinant inactive SufA (lane 2) were
applied in slots to a PVDF membrane. The membrane was incubated with recombinant inactive SufA (10 mgm l
”1) for 18 h at
4 6C. Bound protein was detected with polyclonal rabbit antibodies raised against recombinant SufA. (e) A 10 mg aliquot of
fibrinogen was incubated for 60 min at 37 6C with: lane 1, PBS; lane 2, 30 nM heat-inactivated SufA; lane 3, 30 nM active
SufA. Following incubation, samples were separated by SDS-PAGE under reducing conditions and blotted to a PVDF
membrane. Human serum albumin (10 mg) was used as a negative control (lane 4). The membrane was incubated with
recombinant inactive SufA as in (d) and bound protein was detected with SufA antibodies.
Table 1. SufA-cleaved fragments of plasma proteins and fibrinogen identified by MALDI-TOF
Sample* Protein Accession no.D Peptide
matchd
Coverage (%)§ Peptide residue match|| Expected value
Start End
1 FIBA_HUMAN P02671 14 10 72 271 0.00066
2 FIBA_HUMAN P02671 10 9 39 271 0.045
3 FIBA_HUMAN P02671 19 17 49 287 8.3610
25
4 FIBA_HUMAN P02671 14 13 49 287 2610
28
5 FIBB_HUMAN P02675 26 47 164 491 1.6610
212
*Protein bands: 1, plasma 35 kDa; 2, plasma 32 kDa; 3, fibrinogen 35 kDa; 4, fibrinogen 32 kDa; 5, fibrinogen 58 kDa.
DSwiss-Prot accession number.
dNumber of tryptic peptides matched to the protein.
§Percentage of protein sequence covered by the matched peptides.
||Location of tryptic peptides in protein sequence.
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cally active recombinantly expressed SufA (Karlsson et al.,
2007), followed by antibodies against SufA to detect bound
protein. Fig. 1(d) shows that recombinant SufA interacts
with native fibrinogen. Also the individual Aa,B b and c
chains and their 58 kDa and 35 kDa degradation products,
generated by SufA treatment, interact with the proteinase as
demonstrated by Western blot analysis (Fig. 1e, lanes 1 and
3). The protein bands above 95 kDa in Fig. 1(e), lanes 2 and
3, represent various multimeric forms of SufA present in
the SufA preparation (Karlsson et al., 2007). Such size
heterogeneity is a common property among surface proteins
of Gram-positive bacteria, also following separation by SDS-
PAGE (de Cha ˆteau et al., 1996; Fischetti, 1989; Flores &
Ferrieri, 1996). No binding was observed to human serum
albumin (Fig. 1e, lane 4).
Based on the observation that SufA cleaves fibrinogen, we
tested the effect of the proteinase on the clotting of human
plasma. SufA at different concentrations was incubated
with human citrate-treated plasma for 30 min, and the
amount of fibrinogen available for clotting was analysed by
measuring the thrombin-induced coagulation time (TCT).
The enzyme was found to increase the TCT clotting time in
a dose-dependent manner (Fig. 2), and at a SufA
concentration above 80 nM no measurable clot was
formed. To investigate if SufA influences the intrinsic or
the extrinsic pathways of coagulation, clotting was
measured by the activated partial thromboplastin time
(aPTT) and prothrombin time (PT) respectively. SufA at
concentrations causing prolongation of the TCT (0.2–
40 nM) had no effect on activation of these pathways. At
the highest concentration of SufA however, the aPTT and
PT were substantially affected, most likely due to cleavage
of fibrinogen by SufA. Thus, the data emphasize the
specificity of SufA for fibrinogen resulting in inhibition of
fibrin network formation.
Generation of a F. magna strain lacking SufA
activity
To study the role of SufA when present on the surface of F.
magna, we constructed a sufA mutant by insertion
duplication mutagenesis of ALB8, the strain in which
SufA was originally identified. To our knowledge, there are
no reports of mutants in F. magna or other Gram-positive
anaerobic cocci, so we utilized the suicide vector pFW13
previously used for gene targeting in Streptococcus pyogenes
(Podbielski et al., 1996). pFW13 carries the aacA/aphD
kanamycin-resistance gene and has a ColE1-derived origin
of replication (restricted to replication in relatives of E.
coli). For the transformation procedure, a protocol
modified from a streptococcal electroporation protocol
was used (Simon & Ferretti, 1991) (see Methods).
An internal fragment of the sufA gene, covering the
putative propeptide and a fragment of the putative catalytic
domain, was cloned into the multiple cloning site I of
vector pFW13, resulting in vector pFW-sufA (Fig. 3a),
which was transformed into ALB8 bacteria. The transfor-
mants were kanamycin resistant at concentrations up to
300 mgm l
21. One mutant clone, denoted CK05, was
chosen for further analysis. To confirm vector integration
and sufA disruption, chromosomal DNA from ALB8 and
CK05 was analysed by Southern blotting, using as probes
an aacA/aphD internal fragment and a sufA internal
fragment spanning the EcoRI restriction site. The aacA/
aphD probe only hybridized with a single band of
approximately 2.6 kb of EcoRI CK05 chromosomal DNA
digests (Fig. 3b, left panel). EcoRI digests of ALB8
chromosomal DNA exhibited two positive bands with the
sufA probe, while EcoRI digests of CK05 chromosomal
DNA also showed two additional bands of approximately
1.8 kb and 2.6 kb (Fig. 3b, right panel, indicated with
arrows). For further confirmation of the plasmid integ-
ration, both end regions of the integrated plasmid and the
adjacent disrupted sufA gene were amplified with PCR (Fig.
3a, c). The PCR products 1 and 2 were DNA sequenced
(data not shown); this identified two incomplete copies of
the sufA gene. To conclude, the integration of the suicide
vector yielded a targeted gene disruption of sufA.
When cultivated at 37 uC in an anaerobic environment, the
isogenic mutant CK05 exhibited a similar growth rate to
the wild-type strain ALB8 (data not shown). SufA is
present at the surface of F. magna, but is also found in
substantial amounts in the growth medium (Karlsson et al.,
2007). Therefore, proteins released by papain from the
bacterial surface and culture medium of both wild-type
bacteria (ALB8) and the mutant strain CK05 were analysed
by Western blotting using SufA-specific antiserum. Several
immunoreactive bands between 70 and 250 kDa were
detected in papain digests of ALB8 (Fig. 3d). The bands
below 130 kDa, not found in the culture medium, might be
SufA fragments generated by the papain digestion. No such
bands were detected in the corresponding material from
CK05 (Fig. 3d). However, in the growth medium of this
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Fig. 2. Effect of SufA on the clotting of plasma. Human citrate-
treated plasma was incubated with purified SufA at the indicated
concentrations or, as a control, with 13 mM sodium citrate buffer
for 30 min at 37 6C. The resulting plasma mixtures were analysed
by the TCT test. Data represent means±SD from triplicate
determinations normalized against buffer clotting times.
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reacted with the SufA antibodies (Fig. 3d). These bands
most likely correspond to the expression of a truncated
SufA protein as a consequence of the plasmid integration.
The theoretical molecular mass of truncated SufA contain-
ing the signal peptide is 40.3 kDa whereas the mass is
37.2 kDa without this peptide. This is in accordance with
the size of the protein bands in Fig. 3(d), right panel.
SufA has been shown to efficiently degrade gelatin (Karlsson
et al., 2007), and the various protein preparations were also
analysed by gelatin zymography. As demonstrated in Fig.
3(e), gelatinase activity was present in preparations from the
wild-type ALB8 strain. No such activity could be detected in
the sufA-disrupted strain CK05(Fig. 3e), demonstrating that
disruption of the sufA gene results in the production of a
truncated SufA protein lacking gelatinase activity.
SufA expressing F. magna inhibits coagulation of
human plasma
To analyse the effect of bacteria-bound SufA on fibrin
formation, the two strains ALB8 and CK05 were incubated
with human plasma for 30 min at 37 uC. Following removal
of bacteria, the coagulative state of the resulting super-
natants was measured by TCT. The ALB8 strain prolonged
the clotting times, while CK05, lacking the proteinase, had
no effect (Fig. 4a). The plasma supernatants were also
analysed by SDS-PAGE. Cleavage products of fibrinogen,
corresponding to those obtained in SufA-degraded plasma
(see Fig. 1a), were found in plasma samples incubated with
the SufA-expressing strain ALB8. No such degradation
products could be detected in plasma incubated with the
mutant CK05 strain (data not shown). Fibrinogen alone was
also used to monitor the thrombin-induced coagulation
time. Similarly to whole plasma, SufA-expressing ALB8
prolonged the clotting time whereas CK05 bacteria had no
effect (Fig. 4b). At higher bacterial concentrations (¢10
9
c.f.u. ml
21) no measurable clots were formed in plasma or
fibrinogen solution incubated with ALB8.
SufA produced by F. magna adhering to
keratinocytes prevents the formation of fibrin
networks
Adhesion to cells and cell matrix of the host is essential for
bacterial colonization. Recent work has shown that F.
Fig. 3. sufA gene disruption. (a) Schematic drawing of the strategy to disrupt sufA in F. magna strain ALB8. An internal
1010 bp fragment of the sufA gene (9sufA9) was cloned into the pFW13 vector, generating plasmid pFW-sufA. This plasmid
was transformed into the ALB8 strain for homologous recombination and chromosomal integration, which resulted in the
expression of a truncated SufA protein under control by the putative sufA promoter (P). Hairpin loop transcription terminator
(TT) downstream of the aacA/aphD gene ensured silencing of 9sufA transcription. EcoRI restriction sites are indicated. The
locations of the primer pairs used in PCR analysis are indicated by inverted arrowheads. (b) Southern blot analysis of EcoRI-
digested chromosomal DNA from wild-type strain (ALB8) and the generated strain CK05 (sufA disrupted) separated on
agarose gel. Biotin-labelled fragments of the aacA/aphD and sufA gene were used respectively as probes. The sufA probe
spanned over the EcoRI restriction. (c) PCR analysis using genomic DNA from the ALB8 and CK05 strains as templates. The
primer combinations used in the PCR are as indicated in (a). (d) Western blot analysis of crude protein preparations from strains
ALB8 and CK05. Cell-surface proteins were solubilized using papain and growth medium proteins were concentrated with spin
columns. The protein preparations were separated by SDS-PAGE and transferred to PVDF membranes and probed with
antibodies against recombinant SufA. (e) Proteins in (d) were analysed by gelatin zymography using 8% polyacrylamide and
0.1% porcine gelatin. Proteolytic activities are shown as clearings in the stained gel.
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http://mic.sgmjournals.org 243magna in the skin adheres to BM-40 (also called
osteonectin and SPARC), a protein component of
basement membranes (Frick et al., 2008). However, apart
from basement membranes, BM-40 is widely distributed in
the skin and is abundant at cell–cell contact sites of
keratinocytes (Hunzelmann et al., 1998), suggesting that F.
magna may adhere to keratinocyte cell layers via BM-40.
Confluent monolayers of HaCaT keratinocytes were
therefore incubated for 2 h at 37 uC with bacteria of the
ALB8 and CK05 strains (the expression of BM-40 by the
HaCaT cells used in this study was confirmed by Western
blot analysis of conditioned media and cell extracts).
Following a washing step to remove non-adherent bacteria,
the samples were analysed by scanning electron microscopy
(Fig. 5a, c) and transmission electron microscopy (Fig.
6a, c). Both strains formed large aggregates and adhered
equally well to the keratinocytes.
Normally, F. magna in the epidermis is not exposed to
plasma, but in the case of wounds and inflammatory
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Fig. 4. SufA-expressing F. magna bacteria
inhibit coagulation. Human citrate-treated
plasma (a) or fibrinogen solution at a concen-
tration of 3 mg ml
”1 (b) were preincubated
with F. magna strains ALB8 (h), CK05 (#), or
with 13 mM sodium citrate buffer for 30 min at
37 6C. Bacteria were removed by centrifu-
gation, and the resulting plasma supernatants
were analysed by the TCT test. Data represent
means±SD from triplicate determinations nor-
malized against clotting times for the buffer
control.
Fig. 5. Scanning electron micographs of F. magna adhering to keratinocytes. Keratinocytes were incubated 2 h with ALB8 (a,
b) or CK05 bacteria (c, d). The cells were then washed and incubated with buffer (a, c) or with plasma (b, d) prior to analysis by
scanning electron microscopy. Scale bar: 5 mm.
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244 Microbiology 155reactions (including skin infections), plasma exudate will
cover F. magna with plasma proteins. Keratinocytes express
surface-associated tissue factor (Camerer et al., 1999),
suggesting that fibrin networks could be formed around
adhering bacteria as a result of the plasma exudation. Also,
HaCaT cells express tissue factor as demonstrated by
Western blot analysis of cell extracts and conditioned
media. Furthermore, human citrate-treated plasma pre-
incubated with HaCaT keratinocytes caused a prolongation
oftheTCT, ascompared tocontrolplasma, showing that the
expressed tissue factor activates the extrinsic pathway of
coagulation (data not shown). Sodium citrate-treated
plasma was added to HaCaT cells with adhering F. magna.
Following incubation for 15 min, keratinocytes and bacteria
were washed and examined by electron microscopy. Bacteria
of the CK05 strain, lacking SufA, were embedded by a fibrin
network (Fig. 5d), in contrast to the SufA-expressing ALB8
strain (Fig. 5b). Transmission electron microscopy showed
that bacteria of both strains are surrounded by insoluble
plasma aggregates (Fig. 6b, d). However, fibrin networks
were only found in the vicinity of CK05 bacteria, lacking
SufA (Fig. 6d). The fibrils displayed periodic banding,
typical for fibrin fibrils (Fig. 6d, inset) (Weisel &
Nagaswami, 1992; for references see Wolberg, 2007). The
results suggest that SufA-expressing F. magna, through
cleavage of fibrinogen, prevents the formation of fibrin
networks adjacent to bacteria adhering to keratinocytes.
DISCUSSION
Fibrinogen is the major clotting protein of plasma, which
upon cleavage by thrombin is converted into fibrin. In the
Fig. 6. Transmission electron micrographs of F. magna adhering to keratinocytes. Keratinocytes were incubated 2 h with ALB8
(a, b) or CK05 bacteria (c, d). The cells were then washed and incubated with buffer (a, c) or with plasma (b, d) prior to analysis
by transmission electron microscopy. Fibrin fibrils are indicated (arrows). The insert in (d) shows a higher magnification of a
fibrin fibril. Scale bars: 0.5 mm (left) and 100 nm (right).
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magna, was found to modulate this target protein of the
coagulation cascade and efficiently inhibit the formation of
a fibrin network. In a plasma environment, soluble SufA
specifically and rapidly cleaves fibrinogen, preferentially
removing the C-terminal portion of the fibrinogen Aa
chains (aC) (see Fig. 1a and c). Secondary SufA attacks the
NH2-terminal part of the Bb chains, and higher concen-
trations of the enzyme results in further processing of the
Aa chains. Fibrin assembly involves binding of thrombin to
the central E domain of fibrinogen, followed by a
sequential removal of the NH2-terminal fibrinopeptides A
and B (FPA and FPB) (for references see Mosesson, 2005;
Wolberg, 2007). Thrombin release of FPA is faster than the
release of FPB, and delayed removal of FPA results in
delayed fibrin formation. Interactions between the aC
domains promote lateral fibril associations, clot formation
and stabilization, and fibrinogen lacking these domains
displays increased thrombin clotting time (Collet et al.,
2005; Weisel & Medved, 2001). Thus, the SufA-mediated
inhibition of fibrin network formation could be explained
by the removal of the aC domains. No clot was formed at
high concentrations of SufA, most likely due to removal of
central polymerization sites, where FPA and FPB are
located (see Fig. 1c).
Fibrinopeptides have important effects on inflammation
and are, in particular FPB, potent chemotactic agents for
neutrophils, macrophages and fibroblasts (Persson et al.,
2003; Senior et al., 1986; Singh et al., 1990; Skogen et al.,
1988). The infiltration of neutrophils will provide anti-
bacterial peptides, such as LL-37 (Bals & Wilson, 2003), to
the infectious site. It has also been demonstrated that FPA
and FPB, generated upon thrombin stimulation of human
platelets, exert antibacterial activity against both Gram-
negative and Gram-positive bacteria (Tang et al., 2002).
The level of FPA in plasma treated with SufA was, however,
similar to the control (data not shown), suggesting that
released fibrinopeptides are further degraded and inacti-
vated by the enzyme. Thus, SufA cleavage and inactivation
have been shown for other antibacterial peptides, such as
LL-37 and the chemokine MIG/CXCL9 (Karlsson et al.,
2007). It is also conceivable that the fibrinogen fragments
generated by SufA cleavage are antibacterial. In this
context, it could be speculated that such fragments
preferentially are directed against pathogenic organisms,
favouring growth of commensal bacteria such as F. magna.
Alternatively, SufA-released fibrinogen fragments could
block the activity of antibacterial peptides, as was
demonstrated for glycosaminoglycans released from pro-
teoglycans degraded by bacterial proteinases (Schmidtchen
et al., 2001).
In addition to their haemostatic function, fibrinogen and
fibrin play important roles in wound healing, where the
fibrin network provides a temporary matrix in which cells
can proliferate during wound repair (Drew et al., 2001;
Laurens et al., 2006). Several cellular interactions with
fibrin(ogen) occur through binding to integrins via RGD
sequences located in the aC domains. Apart from its role in
fibrin assembly, the fibrin Bb15242 sequence promotes
fibroblast proliferation, platelet spreading and endothelial
proliferation (Laurens et al., 2006). In addition, fibrinogen
interacts with the inflammatory cytokine interleukin-1b,
enhancing its activity (Sahni et al., 2004) and binds to
fibroblast growth factor-2, platelet-derived growth factor,
and vascular endothelial growth factor. Fibrinogen in these
complexes thereby also potentiates cell proliferation and
migration (Rybarczyk et al., 2003; Sahni & Francis, 2000).
Presumably, the cleavage of fibrinogen by SufA will
modulate not only fibrin polymerization, but also other
fibrinogen-mediated functions of importance during
inflammation and wound healing.
SufA is both secreted and associated with the surface of F.
magna (Karlsson et al., 2007). The soluble SufA used in this
study was purified from the surface of ALB8 bacteria and
despite several purification steps, including ion-exchange
chromatography and gel filtration, the preparation was
heterogeneous. SufA forms dimers/multimers, which are
more proteolytically active than the monomeric form, and
preparations of the enzyme are in general heterogeneous
(Karlsson et al., 2007). In Western blot analyses of the
protein preparation, bands compatible with the size of
monomers and dimers of both the mature SufA and the
pro-enzyme react with antibodies raised against recombin-
ant SufA (see Fig. 1e). Like soluble SufA, whole bacteria
were found to cleave fibrinogen and delay clot formation in
human plasma. Also, on the surface of human keratino-
cytes adherent SufA-expressing F. magna displayed anti-
coagulative properties. In contrast, fibrin networks were
formed around mutant bacteria expressing a truncated and
inactivated form of SufA. The possibility of polar effects on
transcription of downstream genes in the CK05 mutant
strain cannot be completely excluded. To confirm the
entire role of SufA would require complementation of the
gene. However, the cleavage of fibrinogen and delay of clot
formation obtained with soluble SufA demonstrate that the
enzyme exerts potent effects on the formation of fibrin
networks. The host response to a bacterial infection or
tissue damage often results in local activation of coagu-
lation and thrombus formation, providing a barrier against
bacterial spread. However, several bacterial species have
evolved mechanisms to circumvent this host defence by the
expression of proteins activating plasminogen into plas-
min, the host’s clot-dissolving proteinase (for references
see Sun, 2006). For instance, the human pathogen
Streptococcus pyogenes secretes streptokinase, which was
found to be a key virulence factor of this Gram-positive
bacterium, enhancing invasive infection in transgenic mice
expressing human plasminogen (Sun et al., 2004). Thus, to
dissolve fibrin clots facilitates establishment of infection,
and this mechanism plays an important role for many
invasive pathogens (Sun, 2006).
F. magna is a commensal bacterium that inhabits the skin
and other non-sterile body surfaces of the human host, but
it is also an important opportunistic pathogen (Murdoch,
C. Karlsson and others
246 Microbiology 1551998). In vitro SufA is already expressed in the early
exponential growth phase (Karlsson et al., 2007). However,
in vivo the expression of SufA might be regulated to meet the
demand for bacterial survival and proliferation. During
inflammatory conditions upregulation of SufA and inhibi-
tion of fibrin polymerization would favour bacterial spread
to deeper tissue sites, whereas bacteria within a fibrin
network could be protected from innate immune mechan-
isms such as phagocytosis and attack by antibacterial
peptides. To be able to manipulate and modify fibrin
clotting willpresumably add selective advantagestoF.magna
in the normal flora, but may also promote virulence in cases
of clinical infections with this opportunistic pathogen.
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